Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy.
- Author:
Shi-yong QI
1
;
Meng WANG
;
Yong XU
Author Information
1. Research Laboratory of Prostate Diseases, Tianjin Urology Institute, Tianjin 300211, China. yongshiqi@163.com
- Publication Type:Journal Article
- MeSH:
Cancer Vaccines;
therapeutic use;
Dendritic Cells;
cytology;
immunology;
Humans;
Immunotherapy;
Male;
Prostatic Neoplasms;
immunology;
therapy
- From:
National Journal of Andrology
2007;13(5):453-456
- CountryChina
- Language:Chinese
-
Abstract:
As the potent professional antigen present cell, dendritic cells (DC) play an important role in the initiation for anti-tumor immunity. Prostate cancer (PCa) can reduce the number and function of tumor infiltrated dendritic cells (TIDC) by a series of complicated mechanisms, escaping from immunosurveillance. With the development of immunology, more and more studies focus on TIDC and DC-based vaccines for PCa. However, all these studies are still at the exploratory stage. Here is a review of the related literature.
